Comparison of the intraocular pressure following an intravitreal triamcinolone acetonide injection for diabetic macula oedema in vitrectomised and non-vitrectomised eyes

• Published in: BMJ open ophthalmology Vol. 6; no. 1; p. e000620
• Main Authors: Orii, Yusuke, Gozawa, Makoto, Takamura, Yoshihiro, Takeuchi, Yuko, Morioka, Masakazu, Yamada, Yutaka, Matsumura, Takehiro, Sugimoto, Masahiko, Inatani, Masaru
• Format: Journal Article
• Language: English
• Published: England BMJ Publishing Group LTD 01.01.2021; BMJ Publishing Group
• Subjects: Creatinine; Diabetes; Edema; Hemoglobin; Original Research; Patients; Japan; treatment medical
• ISSN: 2397-3269; 2397-3269
• DOI: 10.1136/bmjophth-2020-000620

PurposeTo compare the intraocular pressure (IOP) after an intravitreal triamcinolone acetonide (IVTA) between vitrectomised and non-vitrectomised eyes in patients with diabetes and diabetic macular oedema (DME).DesignRetrospective comparative studyMethodsMedical records of 157 patients (157 eyes) with type 2 diabetes who received IVTA for DME were reviewed, and the best-corrected visual acuity, IOP and optical central retinal thickness (CRT) were compared preoperatively, at 1, 4, 12 and 24 weeks after IVTA between the vitrectomised and non-vitrectomised groups.ResultsIOP significantly increased at 1 (p<0.0001), 4 (p<0.0001), 8 (p<0.0001), 12 (p=0.0019), 16 (p=0.0006) and 20 weeks (p=0.0191) in the non-vitrectomised group, whereas a significant increase was only observed at 1 (p=0.0003) and 4 weeks (p=0.0006) in the vitrectomised group. ΔIOP, IOP changes from baseline, in the non-vitrectomised group was significantly higher than that in the vitrectomised group at 4 (p=0.0014), 8 (p=0.0081), 12 (p=0.0032) and 16 weeks (p=0.0038). No significant difference was observed in logMAR and CRT at any time point after IVTA between the two groups.ConclusionsAfter an initial IVTA, increased IOP and ΔIOP from the baseline IOP were significantly more frequently observed in the non-vitrectomised than that in the vitrectomised group. IVTA is a safer and more effective treatment option for DME in vitrectomised than that in non-vitrectomised eyes.